The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Open accessAbstract
A pathological hallmark of Alzheimer's disease is an accumulation of insoluble plaque containing the amyloid-beta peptide of 40-42 amino acid residues. Prefibrillar, soluble oligomers of amyloid-beta have been recognized to be early and key intermediates in Alzheimer's-disease-related synaptic dysfunction. At nanomolar concentrations, soluble amyloid-beta oligomers block hippocampal long-term potentiation, cause dendritic spine retraction from pyramidal cells and impair rodent spatial memory. Soluble amyloid-beta oligomers have been prepared from chemical syntheses, transfected cell culture supernatants, transgenic mouse brain and human Alzheimer's disease brain. Together, these data imply a high-affinity cell-surface receptor for soluble amyloid-beta oligomers on neurons-one that is central to the pathophysiological process in Alzheimer's disease. Here we identify the cellular prion protein (PrP(C)) as an amyloid-beta-oligomer receptor by expression cloning. Amyloid-beta oligomers bind with nanomolar affinity to PrP(C), but the interaction does not require the infectious PrP(Sc) conformation. Synaptic responsiveness in hippocampal slices from young adult PrP null mice is normal, but the amyloid-beta oligomer blockade of long-term potentiation is absent. Anti-PrP antibodies prevent amyloid-beta-oligomer binding to PrP(C) and rescue synaptic plasticity in hippocampal slices from oligomeric amyloid-beta. Thus, PrP(C) is a mediator of amyloid-beta-oligomer-induced synaptic dysfunction, and PrP(C)-specific pharmaceuticals may have therapeutic potential for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the Aβ binding candidates, cellular prion protein (PrPc) represents the most studied, either alone or through a complex with mGluR5 [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most studied binding partner is the PrPc, which through a cascade involving a complex with mGluR5 may lead to toxicity independently or via tau [37, 62, 72, 79].”
From Transmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredIn the citing paper
“Aβ binds to α7 nicotinic acetylcholine receptors (α7 nAChRs) and to metabotropic glutamate receptors, in particular mGluR5 [31–33].”
From ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease (2017) · cites this paper as [33]
In the citing paper
“A genome-wide association study (GWAS) identified PrPC as a potential high-affinity receptor for oAβ [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“Subsequent studies showed that oAβ, especially high-molecular weight oligomers [88], preferentially bind to PrPC within an N-terminal 95-111aa segment [87].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [87]
In the citing paper
“oligomer binding is significantly reduced in PrPC knock-out cells (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“Aβ oligomers bind with nanomolar affinity to cellular prion protein (PrPC) and that anti-PrP antibodies reduce oligomer binding to neurons and rescue synaptic plasticity (Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“explaining the finding that knocking-down these proteins or adding antibodies against their extracellular domains blocks the accumulation of ADDL clusters (“hotspots”) at synapses (De Felice et al., 2007; Decker et al., 2010a; Lauren et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as Lauren et al., 2009
In the citing paper
“PrPC binds synthetic Aβ oligomers with high affinity and plays a role in the oligomer-mediated inhibition of LTP (17).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“In an elegant study Lauren et al. (17) reported that PrPC mediates the Aβ oligomer-induced hippocampal synaptic plasticity impairment.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“The 22 °C-Aβ oligomers impaired recognition memory in both Prnp +/+ and Prnp 0/0 mice (Fig. 4C).”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [17]
In the citing paper
“When amyloid-β oligomers bind to PrPc, long-term potentiation and the formation of new memories are disrupted [129,130,131].”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722
Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein
Büeler, H., Fischer, M., Lang, Y., Bluethmann, H., Lipp, H., DeArmond, S. J., Prusiner, S. B., Aguet, M., & Weissmann, C. (1992) · Nature · doi:10.1038/356577a0 · Cited by 1,678
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Cited by
Sorted by citations
Items 601–700 of 1,002
Unfolded Protein Response and Macroautophagy in Alzheimer’s, Parkinson’s and Prion Diseases
Milisav, I., Šuput, D., & Ribarič, S. (2015) · Molecules · doi:10.3390/molecules201219865 · Cited by 42
Angelopoulou, E., Paudel, Y. N., Villa, C., Shaikh, M. F., & Piperi, C. (2020) · Biology · doi:10.3390/biology9040086 · Cited by 40
Kelberman, M. A., Anderson, C. R., Chlan, E., Rorabaugh, J. M., McCann, K. E., & Weinshenker, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215546 · Cited by 42
Advances in stem cell therapy in Alzheimer’s disease: a comprehensive clinical trial review
Karvelas, N., Bennett, S., Politis, G., Kouris, N.-I., & Kole, C. (2022) · Stem Cell Investigation · doi:10.21037/sci-2021-063 · Cited by 40
Small but Mighty—Exosomes, Novel Intercellular Messengers in Neurodegeneration
Kumari, M., & Anji, A. (2022) · Biology · doi:10.3390/biology11030413 · Cited by 41
Molecular Structure of Amyloid Fibrils Controls the Relationship between Fibrillar Size and Toxicity
Lee, Y.-J., Savtchenko, R. S., Ostapchenko, V. G., Makarava, N., & Baskakov, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020244 · Cited by 42
Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells
Wojda, U., & Kuźnicki, J. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121984 · Cited by 40
Protein Drug Targets of Lavandula angustifolia on treatment of Rat Alzheimer's Disease.
Zali, H., Azodi, M. Z., Rezaei–Tavirani, M., & Baghban, A. A. (2015) · Europe PMC (PubMed Central) · Cited by 39
Cellular Prion Protein Participates in Amyloid-β Transcytosis across the Blood—Brain Barrier
Pflanzner, T., Petsch, B., André-Dohmen, B., Müller‐Schiffmann, A., Tschickardt, S., Weggen, S., Stitz, L., Korth, C., & Pietrzik, C. U. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.7 · Cited by 41
Phospholipase A2 inhibitors protect against prion and Aβ mediated synapse degeneration
Bate, C., Tayebi, M., & Williams, A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-13 · Cited by 39
Qi, Y., Klyubin, I. V., Harney, S. C., Hu, N., Cullen, W. K., Grant, M. K. O., Steffen, J., Wilson, E. N., Carmo, S. D., Remy, S., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0175-x · Cited by 41
Zhao, C., Lv, C., Li, H., Du, S., Liu, X., Li, Z., Xin, W., & Zhang, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152551 · Cited by 39
Matrix Metalloproteinases, Neural Extracellular Matrix, and Central Nervous System Pathology
Luca, C. D., & Papa, M. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.04.002 · Cited by 39
Functions of the Prion Protein
Hirsch, T. Z., Martin‐Lannerée, S., & Mouillet‐Richard, S. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.06.001 · Cited by 39
Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
Kozin, S. A., Barykin, E. P., Mitkevich, V. A., & Makarov, A. А. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918090079 · Cited by 39
In vivo induction of membrane damage by β-amyloid peptide oligomers
Julien, C., Tomberlin, C., Roberts, C. M., Akram, A., Stein, G. H., Silverman, M. A., & Link, C. D. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0634-x · Cited by 39
Plasma exosomal prion protein levels are correlated with cognitive decline in PD patients
Leng, B., Sun, H., Zhao, J., Liu, Y., Shen, T., Liu, W., Liu, X., Tan, M., Li, F., Zhang, J., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134866 · Cited by 39
Kravenska, Y., Nieznańska, H., Nieznański, K., Lukyanetz, E. A., Szewczyk, A. M., & Koprowski, P. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183337 · Cited by 39
Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight
Forloni, G., Vitola, P. L., Cerovic, M., & Balducci, C. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.11.001 · Cited by 41
The Role of Sphingolipids and Specialized Pro-Resolving Mediators in Alzheimer’s Disease
de Wit, N. M., Mol, K., Rodríguez‐Lorenzo, S., de Vries, H. E., & Kooij, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620348 · Cited by 40
König, A. S., Rösener, N. S., Gremer, L., Tusche, M., Flender, D., Reinartz, E., Hoyer, W., Neudecker, P., Willbold, D., & Heise, H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100499 · Cited by 39
The role of the prion protein in the internalization of α-synuclein amyloids
Cecco, E. D., & Legname, G. (2018) · Prion · doi:10.1080/19336896.2017.1423186 · Cited by 40
Budgett, R. F., Bakker, G., Sergeev, E., Bennett, K. A., & Bradley, S. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.893422 · Cited by 38
When, where and how? Focus on neuronal calcium dysfunctions in Alzheimer’s Disease
Agostini, M., & Fasolato, C. (2016) · Cell Calcium · doi:10.1016/j.ceca.2016.06.008 · Cited by 40
Younan, N. D., Chen, K., Rose, R., Crowther, D. C., & Viles, J. H. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003319 · Cited by 41
Sleep is bi-directionally modified by amyloid beta oligomers
Özcan, G. G., Lim, S., Leighton, P. L. A., Allison, W. T., & Rihel, J. (2020) · eLife · doi:10.7554/elife.53995 · Cited by 39
Sanchez-Varo, R. M., Sánchez‐Mejías, E., Fernandez-Valenzuela, J. J., Castro, V. D., Mejias‐Ortega, M., Gómez-Arboledas, Á., Jiménez, S., Sanchez-Mico, M. V., Trujillo‐Estrada, L., Moreno‐González, I., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.752594 · Cited by 42
Kaushik, M., Kaushik, P., & Parvez, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101577 · Cited by 39
Ion channels induced by the prion protein
Solomon, I. H., Biasini, E., & Harris, D. A. (2012) · Prion · doi:10.4161/pri.6.1.18627 · Cited by 38
Boehm, J. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12251 · Cited by 41
Ostapchenko, V. G., Beraldo, F. H., Guimarães, A. L. S., Mishra, S., Guzmán, M. S., Fan, J., Martins, V. R., Prado, V. F., & Prado, M. A. M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12296 · Cited by 38
Biomarkers of synaptic degeneration in Alzheimer’s disease
Cheng, Q., Fan, Y., Zhang, P., Liu, H., Han, J., Yu, Q., Wang, X., Wu, S., & Lu, Z. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102642 · Cited by 38
A Novel, Drug-based, Cellular Assay for the Activity of Neurotoxic Mutants of the Prion Protein
Massignan, T., Stewart, R. S., Biasini, E., Solomon, I. H., Bonetto, V., Chiesa, R., & Harris, D. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.064949 · Cited by 37
Calero, O., Bullido, M. J., Clarimón, J., Frank, A., Martínez‐Martín, P., Lleó, A., Rey, M. J., Rábano, A., Blesa, R., Gómez‐Isla, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022090 · Cited by 37
A PrPC-caveolin-Lyn complex negatively controls neuronal GSK3β and serotonin 1B receptor
Hernandez-Rapp, J., Martin‐Lannerée, S., Hirsch, T. Z., Pradines, E., Alleaume‐Butaux, A., Schneider, B., Baudry, A., Launay, J., & Mouillet‐Richard, S. (2014) · Scientific Reports · doi:10.1038/srep04881 · Cited by 37
Infliximab ameliorates AD-associated object recognition memory impairment
Kim, D. H., Choi, S., Jho, J., Park, M., Kang, J., Park, S. J., Ryu, J. H., Jo, J., Kim, H. H., & Kim, B. C. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.001 · Cited by 37
Kamps, J., Lin, Y.-H., Oliva, R., Bader, V., Winter, R., Winklhofer, K. F., & Tatzelt, J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100860 · Cited by 37
Extracellular alpha-synuclein: Sensors, receptors, and responses
Domingues, R., Sant’Anna, R., da Fonseca, A. C. C., Robbs, B. K., Foguel, D., & Outeiro, T. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105696 · Cited by 38
Meng, F., Yoo, J., & Chung, H. S. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116736119 · Cited by 38
Kang, M., Kim, S. Y., An, S. S. A., & Ju, Y. R. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.63 · Cited by 37
Ghoshal, N., Calì, I., Perrin, R. J., Josephson, S. A., Sun, N., Gambetti, P. L., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.224 · Cited by 37
Yu, X., Guan, P., Guo, J., Wang, Y., Cao, L., Xu, G., Κωνσταντόπουλος, Κ., Wang, Z., & Wang, P. (2015) · The FASEB Journal · doi:10.1096/fj.15-275578 · Cited by 36
Shah, S. Z. A., Zhao, D., Hussain, T. A., & Yang, L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00120 · Cited by 36
Victor, J., Steger, G., & Riesner, D. (2017) · European Biophysics Journal · doi:10.1007/s00249-017-1270-2 · Cited by 36
Smith, L. K., Kuhn, T. B., Chen, J. C., & Bamburg, J. R. (2018) · Current HIV Research · doi:10.2174/1570162x16666181003144740 · Cited by 36
Evidence for aggregation-independent, PrP C -mediated Aβ cellular internalization
Foley, A. R., Roseman, G. P., Chan, K., Smart, A., Finn, T. S., Yang, K., Lokey, R. S., Millhauser, G. L., & Raskatov, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009238117 · Cited by 38
Feng, B., Freitas, A. E., Gorodetski, L., Wang, J., Tian, R., Lee, Y. R., Grewal, A. S., & Zou, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh2307 · Cited by 38
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 36
Understanding the neurospecificity of Prion protein signaling
Schneider, B. (2010) · Frontiers in bioscience · doi:10.2741/3682 · Cited by 36
Role of PrPC Expression in Tau Protein Levels and Phosphorylation in Alzheimer’s Disease Evolution
Vergara, C., Ordóñez‐Gutiérrez, L., Wandosell, F. G., Ferrer, I., del Rı́o, J. A., & Gavı́n, R. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8793-7 · Cited by 38
Nah, J., Pyo, J.-O., Jung, S., Yoo, S.-M., Kam, T., Chang, J.-W., Han, J., An, S. S. A., Onodera, T., & Jung, Y. (2013) · Autophagy · doi:10.4161/auto.26118 · Cited by 36
Burns, L. H., Pei, Z., & Wang, H. (2023) · Drug Development Research · doi:10.1002/ddr.22085 · Cited by 35
Human prion diseases and the prion protein – what is the current state of knowledge?
Nafe, R., Arendt, C. T., & Hattingen, E. (2023) · Translational Neuroscience · doi:10.1515/tnsci-2022-0315 · Cited by 36
Prion Disease: A Tale of Folds and Strains
Kretzschmar, H. A., & Tatzelt, J. (2013) · Brain Pathology · doi:10.1111/bpa.12045 · Cited by 35
Prion protein in Alzheimer's pathogenesis: a hot and controversial issue
Benilova, I., & Strooper, B. D. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000088 · Cited by 39
Jóźwik, A., Landowski, J., Bidzan, L., Fülöp, T., Bryl, E., & Witkowski, J. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033276 · Cited by 35
RETRACTED: Cognitive Frailty: Mechanisms, Tools to Measure, Prevention and Controversy
Fougère, B., Delrieu, J., del Campo, N., Soriano, G., Sourdet, S., & Vellas, B. J. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2017.03.001 · Cited by 35
RetractedLe, N. T. T., Wu, B., & Harris, D. A. (2018) · Brain Pathology · doi:10.1111/bpa.12694 · Cited by 36
Koike, H., Iguchi, Y., Sahashi, K., & Katsuno, M. (2021) · Molecules · doi:10.3390/molecules26165091 · Cited by 36
Prions and Neurodegenerative Diseases: A Focus on Alzheimer’s Disease
Crestini, A., Santilli, F., Martellucci, S., Carbone, E., Sorice, M., Piscopo, P., & Mattei, V. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215171 · Cited by 35
Liu, S., Li, S., Lin, J., Li, J., & Yang, H. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c00287 · Cited by 36
Martinsson, I., Quintino, L., Garcia, M. G., Konings, S. C., Torres-Garcia, L., Svanbergsson, A., Stange, O., England, R., Deierborg, T., Li, J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.946297 · Cited by 35
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease
Salasova, A., Monti, G., Andersen, O. M., & Nykjaer, A. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00576-2 · Cited by 42
Hamir, A. N., Kehrli, M. E., Kunkle, R. A., Greenlee, J. J., Nicholson, E. M., Richt, J. A., Miller, J. Μ., & Cutlip, R. C. (2011) · Journal of Veterinary Diagnostic Investigation · doi:10.1177/1040638711403404 · Cited by 35
Wilcox, K. C., Marunde, M. R., Das, A., Velasco, P. T., Kuhns, B. D., Marty, M. T., Haoming, J., Luan, C.-H., Sligar, S. G., & Klein, W. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125263 · Cited by 37
Review: PrP 106‐126 – 25 years after
Forloni, G., Chiesa, R., Bugiani, O., Salmona, M., & Tagliavini, F. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12538 · Cited by 34
Complexes of Amyloid-β and Cystatin C in the Human Central Nervous System
Mi, W., Jung, S. S., Yu, W. H., Schmidt, S. D., Nixon, R. A., Mathews, P. M., Tagliavini, F., & Levy, E. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1147 · Cited by 34
Long-standing Prion Dementia Manifesting as Posterior Cortical Atrophy
Depaz, R., Haı̈k, S., Peoc’h, K., Seilhean, D., Grabli, D., Vicart, S., Sarazin, M., de Toffol, B., Remy, C., Fallet‐Bianco, C., et al. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318231e449 · Cited by 34
Context dependent neuroprotective properties of prion protein (PrP)
Steele, A. D., Zhou, Z., Jackson, W. S., Zhu, C., Auluck, P. K., Moskowitz, M. A., Chesselet, M., & Lindquist, S. L. (2009) · Prion · doi:10.4161/pri.3.4.10135 · Cited by 35
Cholesterol Balance in Prion Diseases and Alzheimer’s Disease
Hannaoui, S., Shim, S. Y., Cheng, Y. C., Corda, E., & Gilch, S. (2014) · Viruses · doi:10.3390/v6114505 · Cited by 36
Patented biological approaches for the therapeutic modulation of the 37 kDa/67 kDa laminin receptor
Omar, A., Jovanovic, K., Dias, B. D. C., Gonsalves, D., Moodley, K., Caveney, R. J., Mbazima, V. G., & Weiss, S. F. T. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.539203 · Cited by 34
Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid
Schuster, J., & Funke, S. A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151029 · Cited by 34
Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists
Gunther, E. C., Smith, L. M., Kostylev, M. A., Cox, T. O., Kaufman, A. C., Lee, S., Folta‐Stogniew, E. J., Maynard, G. D., Um, J. W., Stagi, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.021 · Cited by 34
Self-citationMiyamoto, T., Kim, D., Knox, J. A., Johnson, E., & Mucke, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.666529 · Cited by 33
Panes-Fernández, J., Godoy, P. A., Gavilán, J., Ramírez-Molina, O., Burgos, C. F., Marileo, A. M., Flores-Núñez, O., Castro, P. A., Moraga‐Cid, G., Yévenes, G. E., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114596 · Cited by 34
Neuronal transcriptome, tau and synapse loss in Alzheimer’s knock-in mice require prion protein
Stoner, A. J., Fu, L., Nicholson, L., Zheng, C., Toyonaga, T., Spurrier, J. M., Laird, W., Cai, Z., & Strittmatter, S. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01345-z · Cited by 34
Self-citationNeuroprotective and Neurotoxic Signaling by the Prion Protein
Resenberger, U. K., Winklhofer, K. F., & Tatzelt, J. (2011) · Topics in current chemistry · doi:10.1007/128_2011_160 · Cited by 38
PrPC signalling in neurons: From basics to clinical challenges
Hirsch, T. Z., Hernandez-Rapp, J., Martin‐Lannerée, S., Launay, J., & Mouillet‐Richard, S. (2014) · Biochimie · doi:10.1016/j.biochi.2014.06.009 · Cited by 37
Single-Molecule Imaging Reveals Aβ42:Aβ40 Ratio-Dependent Oligomer Growth on Neuronal Processes
Johnson, R. D., Schauerte, J. A., Chang, C.-C., Wisser, K. C., Althaus, J. C., Carruthers, C. J. L., Sutton, M. A., Steel, D. G., & Gafni, A. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2012.12.051 · Cited by 34
Chang, L. Y., Cui, W., Yang, Y., Xu, S., Zhou, W., Fu, H., Hu, S., Mak, S., Hu, J., Wang, Q. L., et al. (2015) · Scientific Reports · doi:10.1038/srep10256 · Cited by 34
Báez-Becerra, C. T., Filipello, F., Sandoval-Hernández, A. G., Arboleda, H., & Arboleda, G. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9845-3 · Cited by 34
Clustering of human prion protein and α-synuclein oligomers requires the prion protein N-terminus
Rösener, N. S., Gremer, L., Wördehoff, M. M., Kupreichyk, T., Etzkorn, M., Neudecker, P., & Hoyer, W. (2020) · Communications Biology · doi:10.1038/s42003-020-1085-z · Cited by 33
Jankovská, N., Olejár, T., & Matěj, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010007 · Cited by 35
Linsenmeier, L., Mohammadi, B., Shafiq, M., Frontzek, K., Bär, J., Shrivastava, A. N., Daμμe, M., Song, F., Schwarz, A., Vela, S. D., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj1826 · Cited by 34
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy
Brody, A. H., Nies, S. H., Guan, F., Smith, L. M., Mukherjee, B., Salazar, S. A., Lee, S., Lam, T. K. T., & Strittmatter, S. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00526-y · Cited by 36
Self-citationA graphene oxide-based fluorescent platform for selective detection of amyloid-β oligomers
Liu, L., Xia, N., Zhang, J., Mao, W., Wu, Y., & Ge, X. (2015) · Analytical Methods · doi:10.1039/c5ay02018b · Cited by 33
Malgieri, G., & Grasso, G. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.10.008 · Cited by 33
The metal-responsive transcription factor-1 protein is elevated in human tumors
Shi, Y. H., Amin, K., Sato, B., Samuelsson, S. J., Sambucetti, L. C., Haroon, Z. A., Laderoute, K. R., & Murphy, B. J. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.6.10979 · Cited by 33
Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease
Han, M., Liu, Y. M., Tan, Q., Zhang, B., Wang, W., Liu, J., Zhang, X., Wang, Y., & Zhang, J. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.065 · Cited by 33
Interaction between Prion Protein and Aβ Amyloid Fibrils Revisited
Nieznański, K., Surewicz, K. A., Chen, S., Nieznańska, H., & Surewicz, W. K. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500019c · Cited by 33
Docking Ligands on Protein Surfaces: The Case Study of Prion Protein
Kranjc, A., Bongarzone, S., Rossetti, G., Biarnés, X., Cavalli, A., Bolognesi, M. L., Roberti, M., Legname, G., & Carloni, P. (2009) · Journal of Chemical Theory and Computation · doi:10.1021/ct900257t · Cited by 33
A cationic tetrapyrrole inhibits toxic activities of the cellular prion protein
Massignan, T., Cimini, S., Stincardini, C., Cerovic, M., Vanni, I., Elezgarai, S. R., Charco, J. M., Stravalaci, M., Negro, A., Sangiovanni, V., et al. (2016) · Scientific Reports · doi:10.1038/srep23180 · Cited by 33
Ulbrich, S., Janning, P., Seidel, R., Matschke, J., Gonsberg, A., Jung, S., Glatzel, M., Engelhard, M., Winklhofer, K. F., & Tatzelt, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197659 · Cited by 33
Current and Emerging Therapies for Alzheimer’s Disease
Nygaard, H. B. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.009 · Cited by 32
Self-citationAdipose Tissue-Derived Stem Cells in Neural Regenerative Medicine
Yeh, D.-C., Chan, T.-M., Harn, H.-J., Chiou, T., Chen, H.-S., Lin, Z.-S., & Lin, S. (2015) · Cell Transplantation · doi:10.3727/096368915x686940 · Cited by 32
Qin, X., Wang, Y., & Paudel, H. K. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738849 · Cited by 33
Wang, X., Kastanenka, K. V., Arbel‐Ornath, M., Commins, C., Kuzuya, A., Lariviere, A., Krafft, G. A., Hefti, F. F., Jerecìć, J., & Bacskai, B. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22979-2 · Cited by 32
Calderón‐Garcidueñas, L., Mukherjee, P. S., Waniek, K., Holzer, M., Chao, C., Thompson, C., Ramos, R. R., Calderón‐Garcidueñas, A. L., Franco-Lira, M., Reynoso-Robles, R., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180853 · Cited by 32
The Effects of YAP and Its Related Mechanisms in Central Nervous System Diseases
Jin, J., Zhao, X., Fu, H., & Gao, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00595 · Cited by 36
Metadata
- Authors
- Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M.
- Affiliations
- Yale University (US)
- Corresponding author
- Strittmatter, Stephen M.
- Venue
- Nature
- Published
- 2009-02
- Volume
- 457
- Issue
- 7233
- Pages
- 1128-1132
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2748841
- OpenAlex
- W2171526610
- Cited by
- 1,560
- References
- 37
- Citations by year
- 2026: 46 · 2025: 45 · 2024: 50 · 2023: 52 · 2022: 87 · 2021: 82 · 2020: 85 · 2019: 71 · 2018: 108 · 2017: 117 · 2016: 103 · 2015: 98 · 2014: 104 · 2013: 116 · 2012: 119
- FWCI
- 87.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- U.S. Public Health Service (5T32GN07205)
- National Institute on Drug Abuse (P30DA018343)
- National Institute of Neurological Disorders and Stroke (R01NS042304, R01NS039962, R37NS033020)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cellular prion protein, amyloid-beta oligomers, Alzheimer's disease, synaptic plasticity, long-term potentiation, cell surface receptors, lipid rafts, hippocampus, anti-PrP antibodies, prion disease, expression cloning, neurotoxicity, spatial memory, neuroprotection, neurodegeneration
- MeSH terms
- Alzheimer Disease, Amyloidosis, Animals, Chlorocebus aethiops, Hippocampus, Humans, Mice, Inbred C57BL, Neuronal Plasticity, Neurons, Peptide Fragments, Prions, Protein Binding, Receptors, Cell Surface, Synapses, Amyloid beta-Peptides, Long-Term Potentiation, COS Cells, Mice, Amyloid Precursor Protein Secretases, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
